Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Navidea Biopharmaceuticals Inc (NAVB)

2.17   0.02 (0.93%) 03-07 03:16
Open: 2.24 Pre. Close: 2.15
High: 2.24 Low: 2
Volume: 226,527 Market Cap: 61M
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates through two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages. Its CD206-targeted drug platform is applicable to a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), imaging and topical gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. Further, the company offers NAV4694, a fluorine-18 labeled PET imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of Alzheimer's disease and mild cognitive impairment. In addition, it is developing diagnostic substances, including Tc99m tilmanocept and other diagnostic applications of its Manocept platform; and various therapeutic development programs. Navidea Biopharmaceuticals, Inc. has a collaboration agreement with IMV Inc. to explore the potential combinatory effect with their platform-based immunotherapies. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was founded in 1983 and is headquartered in Dublin, Ohio.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 2.241 - 2.255 2.255 - 2.268
Low: 1.971 - 1.985 1.985 - 1.999
Close: 2.146 - 2.169 2.169 - 2.191

Technical analysis

as of: 2021-03-05 5:11:03 PM
Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 3.17     One year: 3.68
Support: Support1: 2.00    Support2: 1.66
Resistance: Resistance1: 2.71    Resistance2: 3.15
Pivot: 2.45
Moving Average: MA(5): 2.27     MA(20): 2.53
MA(100): 2.35     MA(250): 2.47
MACD: MACD(12,26): -0.05     Signal(9): 0.01
Stochastic oscillator: %K(14,3): 9.63     %D(3): 6.89
RSI: RSI(14): 40.15
52-week: High: 5.36  Low: 0.63  Change(%): 114.9
Average Vol(K): 3-Month: 33757  10-Days: 29485

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
NAVB has closed above bottom band by 10.2%. Bollinger Bands are 28.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Tue, 02 Mar 2021
Navidea Biopharmaceuticals to Present at the H.C. Wainwright Global Life Sciences Virtual Conference - Yahoo Finance

Tue, 02 Mar 2021
Navidea Biopharmaceuticals Announces $5 Million Private Placement with Existing Investor - Yahoo Finance

Thu, 25 Feb 2021
Should You Buy Navidea Biopharmaceuticals Inc (NAVB) Stock on Thursday? - InvestorsObserver

Tue, 23 Feb 2021
What is Wall Street's Target Price for Navidea Biopharmaceuticals Inc (NAVB) Stock Tuesday? - InvestorsObserver

Wed, 10 Feb 2021
Analyst Rating: Will Navidea Biopharmaceuticals Inc (NAVB) Stock Outperform the Market? - InvestorsObserver

Tue, 09 Feb 2021
Navidea Biopharmaceuticals Inc (NAVB) Up 10.32% in Premarket Trading - InvestorsObserver

Financial Analysis

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Outperform Discounted cash flow: Outperform
Return on Assets: Underperform Price to Earnings: Underperform
Return on Equity: Underperform Debt to Equity: Outperform
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  AMEX
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 26
Shares Float (M) 18
% Held by Insiders 49.21
% Held by Institutions 3.57
Shares Short (K) 198
Shares Short P. Month (K) 215

Stock Financials

EPS -0.550
EPS Est This Year -0.080
EPS Est Next Year -0.030
Book Value (p.s.) -0.100
Profit Margin
Operating Margin -1387.20
Return on Assets (ttm) -89.2
Return on Equity (ttm) -455.8
Qtrly Rev. Growth 4.2
Gross Profit (p.s.) 0.025
Sales Per Share 0.030
EBITDA (p.s.) -0.416
Qtrly Earnings Growth
Operating Cash Flow (M) -8
Levered Free Cash Flow (M) -10

Stock Valuations

PE Ratio -3.95
PEG Ratio
Price to Book value -21.70
Price to Sales 71.60
Price to Cash Flow -6.96

Stock Dividends

Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
Stock Chart
Stoxline Lite
Stoxline Pro
Option Calculator
(c) 2006-2020 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.